Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Oct 23:7:57-59.
doi: 10.1016/j.jdcr.2020.10.020. eCollection 2021 Jan.

A rare presentation of enfortumab vedotin-induced toxic epidermal necrolysis

Andrea Francis  1 , Antonio Jimenez  1 , Swaminathan Sundaresan  2 , Brent Kelly  2
Affiliations
Case Reports

A rare presentation of enfortumab vedotin-induced toxic epidermal necrolysis

Andrea Francis et al. JAAD Case Rep. .
No abstract available

Keywords: MMAE, monomethyl auristatin E; SCORTEN, score of toxic epidermal necrolysis; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis; enfortumab vedotin; general dermatology; medical dermatology; medical oncology; toxic epidermal necrolysis.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Toxic epidermal necrolysis. The patient had demonstrable skin sloughing and erythema on his back.
Fig 2
Fig 2
Toxic epidermal necrolysis. The patient had evident skin sloughing and erythema on the posterior aspect of his bilateral thighs and buttocks.
Fig 3
Fig 3
Biopsy of the right forearm. The patient's biopsy demonstrated an evidence of interface dermatitis with central areas of full-thickness epidermal necrosis/apoptosis, consistent with SJS/TEN spectrum. SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis.
See this image and copyright information in PMC

References

    1. Hanna K.S. Enfortumab vedotin to treat urothelial carcinoma. Drugs Today (Barc) 2020;56(5):329–335. - PubMed
    1. Challita-Eid P.M., Satpayev D., Yang P. Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res. 2016;76(10):3003–3013. - PubMed
    1. Rosenberg J.E., O'Donnell P.H., Balar A.V. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol. 2019;37(29):2592-2600. - PMC - PubMed
    1. M-Rabet M., Cabaud O., Josselin E. Nectin-4: A new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer. Ann Oncol. 2017;28(4):769–776. - PubMed
    1. Zimmerman D., Dang N.H. Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): immunologic reactions. Oncol Crit Care. 2020:267–280.

Publication types

LinkOut - more resources